RFM
VNRX icon

Royal Fund Management’s VolitionRx Ltd VNRX Stock Holding History

Royal Fund Management’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50
Closed -$2K – 656
2018
Q3 		$2K Buy
+50
New +$2.06K ﹤0.01% 466

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Fund Management's VNRX Position: Q4 2018 in Review

Royal Fund Management sold out of VolitionRx Ltd (VNRX) in Q4 2018, closing a stake of 50 shares — an estimated $2K sold.

Royal Fund Management first reported a position in VNRX in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 25 funds tracked by Wall St. Rank hold VNRX as of Q4 2018.

  • Royal Fund Management reported no remaining VolitionRx Ltd position as of Q4 2018 after selling out during the quarter.
  • Royal Fund Management sold 50 VolitionRx Ltd shares in Q4 2018, an estimated $2K.
  • Royal Fund Management first reported a position in VolitionRx Ltd in Q3 2018 and held it in 1 quarter.
  • Royal Fund Management's VolitionRx Ltd position peaked at $2K in Q3 2018.
  • 25 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q4 2018.

Based on Royal Fund Management's 13F filing for Q4 2018, filed 7 May 2020.